Stockscreener 앱 받기
0.3548
5.89%
-0.0222
전일 마감가:
$0.377
열려 있는:
$0.377
하루 거래량:
1.59M
Relative Volume:
2.53
시가총액:
$20.73M
수익:
-
순이익/손실:
$-123.46M
주가수익비율:
-0.137
EPS:
-2.59
순현금흐름:
$-104.11M
1주 성능:
+0.80%
1개월 성능:
-12.63%
6개월 성능:
-28.98%
1년 성능:
-79.13%
1일 변동 폭
$0.3499
$0.379
1주일 범위
$0.3254
$0.415
52주 변동 폭
$0.2601
$2.525
바이오아틀라 Stock (BCAB) Company Profile
명칭
Bioatla Inc
전화
858-558-0708
주소
11085 TORREYANA ROAD, SAN DIEGO
BCAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.3548 | 22.02M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오아틀라 Stock (BCAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | 개시 | JMP Securities | Mkt Outperform |
| 2022-05-05 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-06-28 | 개시 | ROTH Capital | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | BTIG Research | Buy |
| 2021-01-11 | 개시 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | JP Morgan | Overweight |
| 2021-01-11 | 개시 | Jefferies | Buy |
모두보기
바이오아틀라 주식(BCAB)의 최신 뉴스
BioAtla Inc. Stock Analysis and ForecastOutstanding risk-reward balance - PrintWeekIndia
What drives BioAtla Inc. stock priceTriple-digit return opportunities - Autocar Professional
What analysts say about BioAtla Inc. stockConsistently high returns - Autocar Professional
Is Now The Time To Buy BioAtla Inc (NASDAQ: BCAB) Stock? - Stocksregister
Is BioAtla Inc. a good long term investmentHigh-yield market plays - jammulinksnews.com
Is BioAtla Inc. stock a good hedge against inflationFree Consultation - Newser
What analysts say about BioAtla Inc. stock outlookFast Gains With Reduced Risk - beatles.ru
BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting - The Manila Times
What makes BioAtla Inc. stock price move sharplyTrending Stock Alert - Newser
Why BioAtla Inc. stock attracts strong analyst attentionStable Stocks With High Yield - Newser
How BioAtla Inc. stock performs during market volatilityPortfolio Boosting Stock Alerts - Newser
BioAtla (NASDAQ:BCAB) Stock Price Up 2.6% – Here’s Why - Defense World
BioAtla presents Phase I data of BA3182 for metastatic adenocarcinoma - Yahoo Finance
BioAtla Approves 2025 Corporate Bonus Plan - TipRanks
BioAtla, Inc. (NASDAQ:BCAB) Shares Purchased by Two Sigma Investments LP - Defense World
Jane Street Group LLC Purchases 100,204 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla, Inc. (NASDAQ:BCAB) Stock Position Lowered by Two Sigma Advisers LP - Defense World
Millennium Management LLC Cuts Stock Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla (NASDAQ:BCAB) Upgraded by Wall Street Zen to Hold Rating - Defense World
BioAtla presents Phase 2 Oz-V clinical trial data at ASCO 2025 - MSN
Why Did BioAtla Inc (NASDAQ: BCAB) Drop So Much? - Stocksregister
BioAtla reports promising trial results for cancer drug By Investing.com - Investing.com South Africa
BioAtla reports promising trial results for cancer drug - Investing.com
BioAtla (BCAB) Showcases Promising Data for Ozuriftamab Vedotin in Key Cancer Trial | BCAB Stock News - GuruFocus
바이오아틀라 (BCAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.97%
0.22%
자본화:
|
볼륨(24시간):